Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works.

Gilead Sciences and Assembly Biosciences have announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) ...

Objective Estimate the prevalence of human herpesvirus type 1 HSV-1 DNA in placental samples, its incidence in umbilical cord blood of newborns and the associated risk factors. Methods Placental ...

Researchers have found in a new study published in JAMA that valacyclovir showed no efficacy and was associated with ...

According to scientists, the first recorded evidence of kissing dates back nearly 4,500 years to the ancient Middle East.

Nine-ingredient formula featuring L-lysine, elderberry, and botanical extracts positions product among growing category of immune wellness supplements for viral health concernsMiami, Dec. 23, 2025 ...

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

Is there a “least bad” alcohol? Is Benadryl harming your health? Here are the answers you wanted most this year.

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Scientists used a clinical-grade gum in experiments to "substantially" lower viral loads of two herpes simplex viruses and ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on Assembly Biosciences (ASMB) with a $50 price target after the company ...